Co-occurrence of mutations in
DLST
MDH2
NF1
co-occurrent mutations
germline mutation
pheochromocytoma
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
10
2022
accepted:
09
11
2022
entrez:
10
2
2023
pubmed:
11
2
2023
medline:
14
2
2023
Statut:
epublish
Résumé
The percentage of patients diagnosed with pheochromocytoma and paraganglioma (altogether PPGL) carrying known germline mutations in one of the over fifteen susceptibility genes identified to date has dramatically increased during the last two decades, accounting for up to 35-40% of PPGL patients. Moreover, the application of NGS to the diagnosis of PPGL detects unexpected co-occurrences of pathogenic allelic variants in different susceptibility genes. Herein we uncover several cases with dual mutations in NF1 and other PPGL genes by targeted sequencing. We studied the molecular characteristics of the tumours with co-occurrent mutations, using omic tools to gain insight into the role of these events in tumour development. Amongst 23 patients carrying germline NF1 mutations, targeted sequencing revealed additional pathogenic germline variants in DLST (n=1) and MDH2 (n=2), and two somatic mutations in H3-3A and PRKAR1A. Three additional patients, with somatic mutations in NF1 were found carrying germline pathogenic mutations in SDHB or DLST, and a somatic truncating mutation in ATRX. Two of the cases with dual germline mutations showed multiple pheochromocytomas or extra-adrenal paragangliomas - an extremely rare clinical finding in NF1 patients. Transcriptional and methylation profiling and metabolite assessment showed an "intermediate signature" to suggest that both variants had a pathological role in tumour development. In conclusion, mutations affecting genes involved in different pathways (pseudohypoxic and receptor tyrosine kinase signalling) co-occurring in the same patient could provide a selective advantage for the development of PPGL, and explain the variable expressivity and incomplete penetrance observed in some patients.
Identifiants
pubmed: 36760809
doi: 10.3389/fendo.2022.1070074
pmc: PMC9905101
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1070074Subventions
Organisme : Medical Research Council
ID : MR/W001101/1
Pays : United Kingdom
Informations de copyright
Copyright © 2023 Mellid, Gil, Letón, Caleiras, Honrado, Richter, Palacios, Lahera, Galofré, López-Fernández, Calatayud, Herrera-Martínez, Galvez, Matias-Guiu, Balbín, Korpershoek, Lim, Maletta, Lider, Fliedner, Bechmann, Eisenhofer, Canu, Rapizzi, Bancos, Robledo and Cascón.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
PLoS One. 2018 Aug 14;13(8):e0201303
pubmed: 30106970
J Clin Endocrinol Metab. 2015 Feb;100(2):E308-18
pubmed: 25389632
Bioinformatics. 2004 Jul 22;20(11):1797-8
pubmed: 14988123
J Clin Endocrinol Metab. 2021 Jan 23;106(2):459-471
pubmed: 33180916
Am J Hum Genet. 2019 Apr 4;104(4):651-664
pubmed: 30929736
J Med Genet. 2018 Jun;55(6):384-394
pubmed: 29386252
Genet Med. 2018 Dec;20(12):1652-1662
pubmed: 30008476
Cancer Cell. 2013 Jun 10;23(6):739-52
pubmed: 23707781
Best Pract Res Clin Endocrinol Metab. 2020 Mar;34(2):101416
pubmed: 32295730
Front Endocrinol (Lausanne). 2012 Apr 11;3:54
pubmed: 22654872
Clin Cancer Res. 2019 Jan 15;25(2):760-770
pubmed: 30301828
Nat Genet. 2013 Dec;45(12):1479-82
pubmed: 24162739
Clin Cancer Res. 2016 May 1;22(9):2301-10
pubmed: 26700204
Oncotarget. 2019 Oct 15;10(57):5919-5931
pubmed: 31666924
Nat Rev Endocrinol. 2017 Apr;13(4):233-247
pubmed: 27857127
Clin Endocrinol (Oxf). 2017 Jan;86(1):141-149
pubmed: 27460956
Hum Mol Genet. 2012 Dec 15;21(26):5406-16
pubmed: 23010473
Eur J Endocrinol. 2016 Oct;175(4):335-44
pubmed: 27450695
Epigenomics. 2009 Oct;1(1):177-200
pubmed: 22122642
Acta Neuropathol. 2020 Jan;139(1):157-174
pubmed: 31664505
Hum Mol Genet. 2003 Jul 1;12(13):1475-84
pubmed: 12812976
Science. 1994 Jun 10;264(5165):1604-8
pubmed: 8202715
Cancer Res. 2015 Jan 1;75(1):16-21
pubmed: 25381154
J Natl Cancer Inst. 2015 Mar 11;107(5):
pubmed: 25766404
JCO Precis Oncol. 2022 May;6:e2100540
pubmed: 35584348
Cell Tissue Res. 2018 May;372(2):379-392
pubmed: 29427052
Nat Rev Cancer. 2014 Feb;14(2):108-19
pubmed: 24442145
Front Endocrinol (Lausanne). 2019 Aug 20;10:546
pubmed: 31551924
Cancer Res. 2018 Apr 15;78(8):1914-1922
pubmed: 29431636
Hum Mol Genet. 2009 Aug 1;18(15):2768-78
pubmed: 19417008
Endocrine. 2020 Sep;69(3):496-503
pubmed: 32388798
J Med Genet. 2012 Aug;49(8):483-9
pubmed: 22889851
BMJ Case Rep. 2021 May 10;14(5):
pubmed: 33972293
Clin Cancer Res. 2017 Oct 15;23(20):6315-6324
pubmed: 28720665
Oncogene. 2014 May 1;33(18):2279-85
pubmed: 23665675
PLoS Genet. 2014 Oct 16;10(10):e1004575
pubmed: 25329635
Cancers (Basel). 2021 May 14;13(10):
pubmed: 34069252
Eur J Endocrinol. 2018 Feb;178(2):K1-K9
pubmed: 29158289
Science. 2001 Sep 21;293(5538):2256-9
pubmed: 11567139
Neoplasia. 2008 Nov;10(11):1213-21
pubmed: 18953430
Science. 2010 Feb 19;327(5968):1000-4
pubmed: 20167786
Cell Rep. 2022 Mar 1;38(9):110453
pubmed: 35235785
Cancer Cell. 2017 Feb 13;31(2):181-193
pubmed: 28162975
Hum Mol Genet. 2012 Dec 15;21(26):5397-405
pubmed: 22962301
Curr Opin Endocrinol Diabetes Obes. 2021 Jun 1;28(3):283-290
pubmed: 33764930
J Urol. 1999 Nov;162(5):1582-6
pubmed: 10524872
PLoS Comput Biol. 2014 Jan;10(1):e1003440
pubmed: 24453961
Am J Hum Genet. 2021 Oct 7;108(10):1946-1963
pubmed: 34529933
Brain Behav. 2022 Jun;12(6):e2599
pubmed: 35506373
Nat Genet. 2000 Sep;26(1):89-92
pubmed: 10973256
Cancer Genet. 2021 Aug;256-257:110-114
pubmed: 34107390
Nat Commun. 2015 Jan 21;6:6140
pubmed: 25608029
J Med Genet. 2019 Aug;56(8):513-520
pubmed: 30877234
J Clin Endocrinol Metab. 2013 Jul;98(7):2679-81
pubmed: 23837189